Tag: LateStage
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b...
Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s diseaseBIIB122/DNL151 demonstrated...